Prestige biopharma and dr. reddy's announce partnership to commercialize trastuzumab biosimilar in select countries in latin america and southeast asia

Singapore & hyderabad, india--(business wire)-- #drreddy--prestige biopharma and dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, hereafter referred to as “dr. reddy's”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of prestige biopharma's proposed trastuzumab biosimilar in select countries in latin america and southeast asia. prestige biopharma's trastuzumab (hd201) is a
RDY Ratings Summary
RDY Quant Ranking